AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting

Company to exhibit nerve repair technologies at Booth 205

ALACHUA, FL - September 16, 2014 - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced that it will sponsor an educational forum at the American Society for Surgery of the Hand (ASSH) 2014 Annual Meeting, taking place September 18-20 at the John B. Hynes Convention Center in Boston, MA.

The event, entitled "Nerve Matters", will focus on improving outcomes in surgical nerve repair, featuring a discussion by leading nerve repair experts on the latest science, research and innovative treatment approaches. Surgeon panelists will include Peter Evans, MD, PhD, Cleveland Clinic; John V. Ingari, MD, Johns Hopkins; and Bauback Safa, MD, MBA, FACS, The Buncke Clinic. It will be held on Friday, September 19 at the Convention Center in Room 208.

Karen Zaderej, President and Chief Executive Officer for AxoGen commented, "Surgeon education is vitally important given the vast amount of new research and our deeper level of understanding in recent years of techniques for improving outcomes in surgical repair of peripheral nerves. AxoGen is committed to supporting the surgical community by providing opportunities for peer-led forums on these best practices, and we are pleased to invite all surgeons attending ASSH to join this important session."

In addition to sponsoring educational forums, AxoGen will be exhibiting its full portfolio of nerve repair and protection technologies and products at Booth 205 at the ASSH meeting.

About this Event

ASSH Forum 27: Panel Presentation: Nerve Matters
Friday, September 19; 7:00 - 8:00 a.m.
Panelists: Peter Evans MD, PhD, John V. Ingari MD and Bauback Safa MD, MBA, FACS
John B. Hynes Convention Center, Room 208
To Register, click here:

About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

AxoGen, Inc.
Lee Robert "Bob" Johnston, Chief Financial Officer